A Phase I-II Trial of Combined PKCι and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment Options
Latest Information Update: 27 Mar 2024
At a glance
- Drugs Auranofin (Primary) ; Sirolimus (Primary)
- Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer; Small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Jul 2023 Status changed from recruiting to completed.
- 27 Jun 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2023.
- 27 Jun 2022 Planned primary completion date changed from 1 Aug 2022 to 1 Aug 2023.